Key Highlights
- HIMS shares traded up 5.54% to $29.71, versus a prior close of $28.15.
- Hims launched in Germany, including weight management and men's health.
- Management targets at least $600 million of 2026 international revenue.
- A class action lead-plaintiff deadline falls on Nov. 2.
- Q3 earnings are due Nov. 9.
Germany Launch Builds on the Eucalyptus Deal
Hims & Hers (NYSE:HIMS) shares traded up 5.54% to $29.71 after the telehealth company announced its launch in Germany, including its weight management offering and deeper investment in men's health. The launch builds on its international expansion after the June Eucalyptus deal.
Management is targeting at least $600 million of international revenue in 2026. The shares outpaced the sector, which is near a record high after an Oppenheimer upgrade.
Legal and Regulatory Overhangs Persist
Law firms are reminding investors of a Nov. 2 lead-plaintiff deadline in a class action tied to the July FTC complaint. Regulatory exposure, along with compounded GLP-1 sales, remains a central issue for the stock.
Subscriber Growth Meets Thin Profits
Hims had more than 2.5 million subscribers at the end of 2025 and reported about $1.48 billion in 2024 revenue. Earnings per share are a loss of $0.64, and the forward price-to-earnings ratio is 85.67. The market capitalization is about $6.68 billion.
Shares trade against a 52-week range of $13.74 to $51.36. Consensus is Hold with targets in the low $30s, so most analysts see the stock near fair value.
Q3 Earnings on Nov. 9 Will Test International Margins
Investors look to Q3 earnings on Nov. 9 for international profitability and margins, as well as an update on the legal matters.






Please wait processing your request...